Teleflex is a medical-device company with 29% growth, rising earnings estimates and strong momentum, but at $136.29 the price is already 1.7% above the $133.98 analyst target and quality is only 4.5/10 with 15% short interest.
Thesis pillars
- Moderate Quality Leverage→Stable
- Strong Growth Leader→Stable
- Earnings Beats Estimates Rising↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Feb 27, 2026
Teleflex Incorporated (TFX) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $149.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.1% away).
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical... Read more
Hold if already holding. Not a fresh buy at $149.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 6.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 28, 2026Recent Developments — Teleflex Incorporated
Latest news
- NEWS FDA Device Breakthrough Might Change The Case For Investing In Teleflex Stock (TFX) - Yahoo Finance Singapore — Yahoo Finance Singapore Oct 28, 2026 positive
- NEWS FDA Device Breakthrough Might Change The Case For Investing In Teleflex Stock (TFX) - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Teleflex Inc. stock outperforms competitors on strong trading day - MarketWatch — MarketWatch Oct 27, 2026 positive
- NEWS Does Full Study Enrollment Change The Bull Case For Teleflex (TFX)? - Simply Wall Street — Simply Wall Street Oct 14, 2026 positive
- NEWS Truist Securities Adjusts Teleflex Price Target to $142 From $150, Maintains Hold Rating - Yahoo Finance — Yahoo Finance Oct 14, 2026 negative
Latest item Oct 28, 2026 · Generated 2026-11-05T11:34:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMJason Weidman appointed as President and CEO effective June 8, 2026, replacing interim CEO Stuart A. Randle, who continues as a Board member. Weidman joins from Medtronic.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $149.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Analyst target $133.98 reached (−10.6%), stop $141.35 (−6.0%), A.R:R -0.7:1. Score 6.2/10, moderate confidence.
Analyst target $133.98 reached (−10.6% from $149.87); no take-profit level is published. Analyst target $133.98 reached (−10.6%), stop $141.35 (−6.0%), A.R:R -0.7:1. Stop-loss: $141.35.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
Teleflex Incorporated trades at a P/E of N/A (forward 13.7). TrendMatrix value score: 6.0/10. Verdict: Hold.
18 analysts rate TFX, with a consensus score of 3.6/5. 11 analysts publish price targets averaging $154.
What does Teleflex Incorporated do?Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas,...
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical products to hospitals worldwide through a direct sales force and distributors. In December 2025, Teleflex announced $2.0 billion in pending divestitures of its Acute Care, Interventional Urology, and OEM businesses.